Multiple news outlets are reporting that President Trump is set to fire Food and Drug Administration Commissioner Marty Makary, according to a PBS NewsHour segment featuring health policy reporter Liz Whyte of the Wall Street Journal. The potential removal would come after what has been described as a tumultuous tenure since Makary's installation as FDA head last year.
Makary, a surgeon and medical commentator, was appointed to lead the agency following his confirmation by the Senate. His time at the FDA has been marked by various challenges that have drawn scrutiny from multiple directions.
What the Right Is Saying
Conservative critics of Makary have argued that his approach to regulation was insufficiently aligned with the administration's broader agenda. Some Republican voices have suggested that Makary's tenure saw the FDA move too slowly on certain deregulatory initiatives or, conversely, not fast enough on approvals prioritized by industry supporters.
The Trump administration has not issued a formal statement confirming plans to remove Makary as of this reporting. Supporters of the potential change argue that new leadership could better align the agency with White House priorities. Other conservative voices have urged caution, noting that stability at the FDA is important for pharmaceutical and medical device industries that rely on predictable regulatory pathways.
What the Left Is Saying
Progressive Democrats and public health advocates have expressed concern about Makary's leadership at the FDA throughout his tenure. Critics on the left have pointed to what they describe as regulatory decisions that they say favored industry interests over robust public health protections. The uncertainty around Makary's position comes as Congress continues to debate healthcare policy priorities.
Democratic lawmakers have not issued formal statements specifically addressing Makary's potential firing, as the news broke only recently through media reports. Health policy advocates who have monitored FDA decisions under Makary say they are watching developments closely but would need to see specific actions before commenting on what a leadership change might mean for regulatory approaches.
What the Numbers Show
The FDA under Makary has processed hundreds of drug and device applications during his tenure. Specific approval rates, review timelines, and enforcement actions during his time as commissioner would require data from agency reports that have not yet been compiled in full for this story. Congressional oversight records, if any exist regarding Makary's specific decisions, had not been publicly released at time of publication.
The Senate confirmation process for FDA commissioners typically requires significant bipartisan support. Makary's initial confirmation vote and any potential replacement would follow standard procedures under the Federal Food, Drug, and Cosmetic Act.
The Bottom Line
The reported plan to remove Commissioner Makary remains unconfirmed by official sources as of this writing. If accurate, it would represent a significant shakeup at an agency responsible for regulating food safety, pharmaceuticals, medical devices, and other consumer products affecting hundreds of millions of Americans. A replacement nominee would face Senate confirmation under standard procedures. The pharmaceutical industry, healthcare providers, and public health advocates are expected to closely monitor any formal announcement from the White House regarding Makary's status.
This story is developing. Readers should consult official government communications for confirmed information about FDA leadership changes.